||A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease.
||Flaviano Giorgini, Paolo Guidetti, QuangVu Nguyen, Simone C Bennett, Paul J Muchowski
||Huntington disease is a fatal neurodegenerative disorder caused by expansion of a polyglutamine tract in the protein huntingtin (Htt), which leads to its aggregation in nuclear and cytoplasmic inclusion bodies. We recently identified 52 loss-of-function mutations in yeast genes that enhance the toxicity of a mutant Htt fragment. Here we report the results from a genome-wide loss-of-function suppressor screen in which we identified 28 gene deletions that suppress toxicity of a mutant Htt fragment. The suppressors are known or predicted to have roles in vesicle transport, vacuolar degradation, transcription and prion-like aggregation. Among the most potent suppressors was Bna4 (kynurenine 3-monooxygenase), an enzyme in the kynurenine pathway of tryptophan degradation that has been linked directly to the pathophysiology of Huntington disease in humans by a mechanism that may involve reactive oxygen species. This finding is suggestive of a conserved mechanism of polyglutamine toxicity from yeast to humans and identifies new candidate therapeutic targets for the treatment of Huntington disease.
||Nat. Genet. 2005; 37:526-31
These data may contain errors.
YeastPhenome.org is running in beta version.
The data are available for download, but, as of today, we cannot guarantee the absence of errors or code bugs introduced during processing.
This warning will be removed after all cross-checks and validations have been completed.
In the meantime, please, be careful when using the data.